Tom Powles: IMVIGOR011 Trial Brings ctDNA-Guided Adjuvant Immunotherapy to Bladder Cancer
Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last.”
Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, shared this post, adding:
“Huge congratulations Tom Powles on leading this massive practice changing trial, the 1st biomarker driven trial informing adjuavant IO therapy in MIBC.”
Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), added a comment to this post:
“Congratulations Tom Powles and the team. These practice-changing data have brought ctDNA testing to the forefront of decision-making regarding adjuvant therapy in our patients with bladder cancer.”
Read More About IMvigor011 Trial on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023